Clarity Pharmaceuticals hits target for SECuRE trial cohort

• Clarity Pharmaceuticals reached its recruitment target of 16 participants in the main group of its Phase 1/2a SECuRE trial.
• The company continues participant enrolment for a combination treatment arm using enzalutamide to evaluate further trial benefits.
• Clarity aims to assess product efficacy in 24 total prostate cancer patients while preparing plans for a Phase 3 trial.

Clarity Pharmaceuticals (ASX:CU6) completed recruitment for the main group of its Phase 1/2a SECuRE trial evaluating 16 patients with metastatic castration-resistant prostate cancer.

The trial aims to assess treatment safety across a target group of 24 total participants before they receive taxane or radioligand-based therapies.

"Our SAR-bisPSMA programmes continue to generate an impressive evidence base in clinical trials and real-world case profiles," said Clarity Pharmaceuticals Executive Chairperson Dr Alan Taylor.

Data from 19 participants reported on Aug. 5 showed that 74% achieved a prostate-specific antigen reduction of at least 25% after receiving treatment cycles.

The business is now planning a registrational Phase 3 trial based on preliminary trial results.

Following the announcement, the Clarity Pharmaceuticals share price was unchanged at $1.96.

Clarity develops clinical-stage radiopharmaceutical products designed to improve treatment outcomes for cancer patients.

The business evaluates therapy options using copper isotopes to target prostate-specific membrane antigen settings across various stages of disease.